NCATS' rare disease program backs stem cell project and Lilly R&D

09/12/2013 | NIH News

The NIH's National Center for Advancing Translational Sciences will fund four research projects related to blindness and heart conditions, and the funding marks the NCATS Therapeutics for Rare and Neglected Diseases program's first collaboration with a large drugmaker as well as its first use of stem cells. A University of California, Irvine, project will explore retinitis pigmentosa treatments using retinal progenitor cells. An Eli Lilly and Co. program will focus on the treatment of hypoparathyroidism with a long-acting parathyroid hormone analog.

View Full Article in:

NIH News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Director, Payer Marketing
Avalere Health
Washington, DC
Actuary
Meridian Health Plan
Detroit, MI
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX